Leading Pharma recalls 25mg Clomipramine capsules with high drug content
Leading Pharma recalls 25mg Clomipramine hydrochloride capsules (NDC 69315-167-01) due to higher-than-stated drug content. This may cause overdose risk if taken as prescribed.
Lower-risk recall
Superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules
Contact the company
What happened, in plain English
Leading Pharma is recalling 25mg Clomipramine hydrochloride capsules because they contain 110.6% of the labeled drug amount. This could lead to overdose if taken as directed, especially since these are prescription-only medications. Read more at govinfonow.com/recall/34358-leading-pharma-recalls-25mg-clomipramine-capsules-with-high-drug-content.
Source Summary by GovInfoNow · govinfonow.com/recall/34358-leading-pharma-recalls-25mg-clomipramine-capsules-with-high-drug-content · Updated August 18, 2026 · FDA enforcement record: FDA #D-1546-2022
Cite this page
“Leading Pharma recalls 25mg Clomipramine capsules with high drug content.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34358-leading-pharma-recalls-25mg-clomipramine-capsules-with-high-drug-content. Based on FDA recall #D-1546-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1546-2022%22&limit=1).
Why it’s dangerous
The capsules contain 110.6% of the labeled drug amount, meaning each capsule has more active ingredient than specified. This could lead to an overdose if taken as directed, though the risk is low since these are prescription-only medications.
Who’s affected
Prescription patients who have the specific 25mg capsules with NDC 69315-167-01. Those most at risk are individuals who might take more than intended due to the higher drug content.
How to tell if you have this one
Check for the product name 'Clomipramine Hydrochloride Capsules, USP 25mg', 100-count bottles, manufactured by Leading Pharma, LLC, with NDC 69315-167-01 and lot number B14221.
- Brand
Leading Pharma- Category
Drug
What to do — step by step
Check Product Details
Verify the product label includes NDC 69315-167-01 and lot number B14221.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 13 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Leading Pharma recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1546-2022 (August 23, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1546-2022 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.